Frank D Gotch Deceased6548 King George Way, Morrow, GA 30260

7097630, Aug 29, 2006

Feb 27, 2003

10/375899

Frank A. Gotch - San Francisco CA, US
Thomas I. Folden - Alamo CA, US

Fresenius Medical Care North America - Lexington MA

A61M 37/00
B01D 11/00
B01D 21/24
C02F 9/00
C02F 1/44

604 501, 604 401, 604 609, 604 61, 210646, 2101952, 21032165, 210420

This invention provides a method and apparatus for calculating a hemodialysis parameter, especially blood access flow rate, using multiple dialysance values. The dialysance values may be calculated based upon either sodium or urea concentrations. One dialysance value can be determined for conditions in which a patient's arterial line withdraws blood from an upstream location in a patient's fistula and treated blood is returned by a venous line to a downstream location in a patient's fistula. The second dialysance value can be determined when the lines have been reconfigured so that the arterial line withdraws blood from a downstream portion of a patient's fistula and the venous line returns treated blood to an upstream portion of a patient's fistula. Since it is possible to determine the dialysance values solely from concentration measurements made on the dialysate side of the dialysis apparatus, the present method and apparatus provide a non-invasive means for determining hemodialysis parameters such as blood access flow rate and recirculation.

8182692, May 22, 2012

May 28, 2008

12/128167

Frank A. Gotch - San Francisco CA, US

Fresenius Medical Care Holdings, Inc. - Waltham MA

B01D 61/32
B01D 61/24

210646, 210645, 210647, 210739, 210745, 210746, 604 401, 422 681, 422 8201, 422 8202

Solutions, dialysates, and methods for measuring solutes in blood and/or for treating blood. In one aspect of the invention, a method of performing dialysis includes placing a solution in communication with blood of a subject, where a concentration of at least one electrically conductive solute in the solution, prior to being placed in communication with the blood of the subject, is substantially equal to a concentration of the at least one electrically conductive solute in the blood of the subject.

2010009, Apr 22, 2010

Oct 16, 2009

12/580803

Frank A. Gotch - San Francisco CA, US
Benjamin J. Lipps - Boston MA, US
Peter Kotanko - New York NY, US
Nathan W. Levin - New York NY, US
Amanda K. Stennett - Waltham MA, US
Norman J. Ofsthun - Lexington MA, US

Fresenius Medical Care Holdings, Inc. - Waltham MA

B01D 61/34

210647

The invention is directed to a method of determining a dosage of phosphorus binder for a patient undergoing dialysis treatment to achieve a pre-dialysis serum phosphorus concentration within a desired concentration range while achieving a desired net accumulation of calcium. The method includes determining the dosage of phosphorus binder that will achieve pre-dialysis serum phosphorus concentration of the patient that is within the desired concentration range while accounting for the change in the amount of phosphorus removed by the dialysis treatment when the pre-dialysis serum phosphorus concentration of the patient is within the desired concentration range, determining a dialysate calcium concentration that will result in the desired net accumulation of calcium over a complete dialysis cycle, and dialyzing the patient with a dialysate containing a calcium concentration based upon that determination.

2012018, Jul 19, 2012

Oct 1, 2010

13/499485

Frank A. Gotch - San Francisco CA, US
Amanda K. Stennett - Waltham MA, US
Norma J. Ofsthun - Lexington MA, US

G01N 35/00
G06G 7/60

436 43, 703 11

A method of identifying a patient who is non-compliant with prescribed diet and/or phosphate binder regimen calculates a phosphorus-protein ratio (PPR) by calculating the patient's protein intake, measuring the patient's serum phosphorus concentration, and estimating the amount of phosphorus removed by the patient's kidneys from measured residual urea clearance. The PPR is the ratio between the total amount of phosphorus removed from the patient and the patient's protein intake. The method enables identifying a patient that is non-compliant with prescribed diet and/or phosphate binder regimen if the PPR is outside of an acceptable range.

6648845, Nov 18, 2003

Jan 7, 1998

09/003798

Frank A. Gotch - San Francisco CA
Thomas I. Folden - Alamo CA

Fresenius Medical Care North America - Lexington MA

A61M 3700

604 501, 604 401, 600505, 210646

This invention provides a method and apparatus for calculating a hemodialysis parameter, especially blood access flow rate, using multiple dialysance values. The dialysance values may be calculated based upon either sodium or urea concentrations. One dialysance value can be determined for conditions in which a patients arterial line withdraws blood from an upstream location in a patients fistula and treated blood is returned by a venous line to a downstream location in a patients fistula. The second dialysance value can be determined when the lines have been reconfigured so that the arterial line withdraws blood from a downstream portion of a patients fistula and the venous line returns treated blood to an upstream portion of a patients fistula. Since it is possible to determine the dialysance values solely from concentration measurements made on the dialysate side of the dialysis apparatus, the present method and apparatus provide a non-invasive means for determining hemodialysis parameters such as blood access flow rate and recirculation.